MNPR FY2025 EPS Lifted by Brookline Capital Management

Key Points

• Brookline Capital Management raised its FY2025 earnings estimate for Monopar Therapeutics to ($2.33) per share, up from ($2.53), but still below the consensus estimate of ($1.65).
• Monopar Therapeutics' stock has been rated as a "Moderate Buy" with a target price averaging at $60.00, supported by increased coverage from several analysts.
• Insider selling activity has been noted, with directors selling a combined total of 25,704 shares, signaling a significant reduction in their ownership stakes.

Monopar Therapeutics Inc. (NASDAQ:MNPR - Free Report) - Equities researchers at Brookline Capital Management lifted their FY2025 earnings estimates for Monopar Therapeutics in a research report issued to clients and investors on Tuesday, August 12th. Brookline Capital Management analyst K. Dolliver now forecasts that the company will earn ($2.33) per share for the year, up from their previous forecast of ($2.53). The consensus estimate for Monopar Therapeutics' current full-year earnings is ($1.65) per share.

MNPR has been the topic of several other reports. Cantor Fitzgerald started coverage on shares of Monopar Therapeutics in a research note on Monday, July 7th. They set an "overweight" rating and a $74.00 target price on the stock. Wall Street Zen raised shares of Monopar Therapeutics from a "sell" rating to a "hold" rating in a research note on Thursday, May 22nd. Finally, Chardan Capital reaffirmed a "buy" rating and issued a $60.00 price objective on shares of Monopar Therapeutics in a research note on Wednesday. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $60.00.

Monopar Therapeutics Trading Down 2.9%

NASDAQ MNPR traded down $1.03 on Friday, hitting $34.83. 1,377 shares of the company were exchanged, compared to its average volume of 39,515. The company has a market cap of $214.90 million, a PE ratio of -10.46 and a beta of 1.05. Monopar Therapeutics has a 12 month low of $2.15 and a 12 month high of $54.30. The stock has a fifty day moving average of $38.04 and a 200-day moving average of $37.87.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last posted its quarterly earnings data on Tuesday, August 12th. The company reported ($0.35) earnings per share for the quarter, topping the consensus estimate of ($0.47) by $0.12.

Institutional Trading of Monopar Therapeutics

A number of large investors have recently added to or reduced their stakes in MNPR. Police & Firemen s Retirement System of New Jersey purchased a new stake in Monopar Therapeutics during the second quarter worth about $34,000. AlphaQuest LLC purchased a new position in shares of Monopar Therapeutics in the first quarter worth about $44,000. JPMorgan Chase & Co. purchased a new position in shares of Monopar Therapeutics in the fourth quarter worth about $45,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in shares of Monopar Therapeutics in the second quarter worth about $80,000. Finally, New York State Common Retirement Fund purchased a new position in shares of Monopar Therapeutics in the second quarter worth about $104,000. Hedge funds and other institutional investors own 1.83% of the company's stock.

Insider Activity at Monopar Therapeutics

In related news, Director Kim R. Tsuchimoto sold 8,904 shares of the firm's stock in a transaction dated Monday, July 14th. The shares were sold at an average price of $40.00, for a total transaction of $356,160.00. Following the transaction, the director directly owned 11,486 shares of the company's stock, valued at $459,440. This trade represents a 43.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Christopher M. Starr sold 16,800 shares of the firm's stock in a transaction dated Monday, July 14th. The stock was sold at an average price of $40.00, for a total transaction of $672,000.00. Following the sale, the director owned 5,173 shares of the company's stock, valued at $206,920. This trade represents a 76.46% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 42,504 shares of company stock valued at $1,700,160 over the last ninety days. Corporate insiders own 20.50% of the company's stock.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.